Welcome to Celleron Therapeutics
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer.
Our mission
Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron’s vision is that the future of cancer therapy lies in the ability to match patients
David Kerr, CBE
Press releases
Celleron Therapeutics announces Initiation of Patient Enrolment into the Expansion Cohort of its CXD101 Phase 1 Clinical Trial
The expansion cohort of our Phase I clinical trial is open to patient enrolment.
Celleron Therapeutics Selects Syneos Health to Conduct Clinical Trial Programme for CXD101 on MAY 1, 2018
The company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.
Celleron Therapeutics announces MHRA Clinical Trial Authorisation for CXD102 in Microsatellite-Stable Colorectal Cancer
UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.
Clinical products
CXD101
Celleron’s proprietary drug, CXD101, is a dual mechanism HDAC inhibitor with multiple properties that differentiate it from competing compounds. CXD101 is a novel epigenetic immune-regulator which has the ability to enhance immune recognition of tumour cells.
CXD201
CXD201 is a proprietary topoisomerase inhibitor with multiple points of difference from competing products. CXD201 is derived from the homocamptothecin family, exhibiting a unique chemical composition and improved pharmacological properties.